SCHEMBL5724205

SCHEMBL5724205

CC(C)(C)[Si](OC1CN(c2nc(C(=O)N3CCCC3)cs2)C1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HPGD P15428 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39
HTR2C P28335 1/20 0.38
SCD O00767 1/20 0.37
PTK2 Q05397 1/20 0.37
LMNA P02545 2/20 0.37
MAPK1 P28482 1/20 0.37
GNE Q9Y223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724198 0.99 MEN1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5724278 0.98 MEN1 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5724107 0.92 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL5724414 0.92 SCD (0.36) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5724451 0.92 HTR2C (0.45) KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL5724521 0.89 RIPK1 (0.37) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL5724728 0.88 PTGER1 (0.41) ALDH1A1L3MBTL1KDM4ESCDPTGER1
SCHEMBL5724070 0.86 SCD (0.48) SMN1; SMN2NPC1RAB9AL3MBTL1SCD
SCHEMBL5723546 0.84 OGA (0.42) L3MBTL1SCDHRH3
SCHEMBL5723511 0.84 OGA (0.38) SMN1; SMN2NPC1RAB9AL3MBTL1SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD MEN1 1170/4885KMT2A 2404/4885SMN1; SMN2 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.